famotidine has been researched along with Liver Cirrhosis in 6 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine clearance was reduced only in patients with decompensated cirrhosis, probably because of concomitant renal impairment." | 5.28 | Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer. ( Ohnishi, K, 1990) |
| "The pharmacokinetics of famotidine were studied after the administration of a single intravenous dose of 20-mg to seven normal volunteers, six patients with chronic hepatitis, 14 patients with compensated cirrhosis, and seven patients with decompensated cirrhosis." | 3.68 | Pharmacokinetics of famotidine after intravenous administration in liver disease. ( Ohnishi, K, 1991) |
| "The effect of ranitidine 300 mg po given at 1800 h (famotidine 40 mg/cimetidine 800 mg) on the night time gastric pH was tested using longterm intragastric pH monitoring in 27 patients with and 32 patients without liver cirrhosis." | 3.67 | Frequent non-response to histamine H2-receptor antagonists in cirrhotics. ( Bode, JC; Klotz, U; Krishna, DR; Walker, S, 1989) |
| " The mean half-life in the compensated cirrhotics, 2." | 1.28 | Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ( Cottrell, J; Mann, SG; Morgan, MY; Stambuk, D, 1990) |
| "Famotidine clearance was reduced only in patients with decompensated cirrhosis, probably because of concomitant renal impairment." | 1.28 | Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer. ( Ohnishi, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dumas, F | 1 |
| Baldit, C | 1 |
| Couzigou, P | 1 |
| Bannwarth, B | 1 |
| Vincon, G | 1 |
| Orlando, R | 1 |
| Okolicsanyi, L | 1 |
| Ohnishi, K | 2 |
| Morgan, MY | 1 |
| Stambuk, D | 1 |
| Cottrell, J | 1 |
| Mann, SG | 1 |
| Walker, S | 1 |
| Krishna, DR | 1 |
| Klotz, U | 1 |
| Bode, JC | 1 |
6 other studies available for famotidine and Liver Cirrhosis
| Article | Year |
|---|---|
Pharmacokinetics of famotidine in patients with liver cirrhosis.
Topics: Famotidine; Humans; Liver Cirrhosis | 1993 |
Pharmacokinetic studies of famotidine in patients with liver cirrhosis.
Topics: Famotidine; Humans; Liver Cirrhosis | 1992 |
Pharmacokinetics of famotidine after intravenous administration in liver disease.
Topics: Adult; Aged; Chronic Disease; Famotidine; Female; Half-Life; Hepatitis; Humans; Infusions, Intraveno | 1991 |
Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Chronic Disease; Famotidine | 1990 |
Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer.
Topics: Adult; Chronic Disease; Famotidine; Female; Hepatitis; Humans; Liver Circulation; Liver Cirrhosis; L | 1990 |
Frequent non-response to histamine H2-receptor antagonists in cirrhotics.
Topics: Anti-Ulcer Agents; Cimetidine; Esophagitis, Peptic; Famotidine; Female; Gastric Acidity Determinatio | 1989 |